Persistence of apremilast in moderate‐to‐severe psoriasis: a real‐world analysis of 14 147 apremilast‐ and methotrexate‐naive patients in the French National Health Insurance database-Reference-Cited by-同舟云学术

Persistence of apremilast in moderate‐to‐severe psoriasis: a real‐world analysis of 14 147 apremilast‐ and methotrexate‐naive patients in the French National Health Insurance database

Published:2019-07-22 Issue:3 Volume:182 Page:690-697
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Sbidian E.¹²³⁴^ORCID,Billionnet C.¹,Weill A.¹,Maura G.¹,Mezzarobba M.¹

Affiliation:

1. Département d'Etudes en Santé Publique Direction de la Stratégie des Etudes et des Statistiques, Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (CNAM) Paris F‐75020 France

2. AP‐HP, Hôpitaux Universitaires Henri Mondor Département de Dermatologie Université Paris‐Est Créteil Créteil F‐94010 France

3. INSERM Centre d'Investigation Clinique 1430 Créteil F‐94010 France

4. EA 7379 EpidermE Université Paris‐Est Créteil Créteil F‐94010 France

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18047

Reference38 articles.

1. Psoriasis

2. U.S. Food and Drug Administration.Drugs@FDA: FDA approved drug products. Available at:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206088(last accessed 12 June 2019).

3. European Medicines Agency.Otezla. Available at:https://www.ema.europa.eu/en/medicines/human/EPAR/otezla(last accessed 12 June 2019).

4. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

5. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psoriasis and Related Disorders;Rook's Textbook of Dermatology;2024-03-19

2. Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis;Biologics: Targets and Therapy;2023-10

3. The limitations of persistence as a measure of efficacy of biologic therapies;British Journal of Dermatology;2023-09-06

4. Dermoscopic Prediction of Therapeutic Response in Psoriatic Lesions Treated with Methotrexate and Apremilast: An Observational Study on Skin Color;Journal of Skin and Stem Cell;2023-02-17

5. Real-world registry-based study on apremilast use in psoriasis and psoriatic arthritis in Finland;Scandinavian Journal of Rheumatology;2023-01-16